Clinical trial
GALLANT 22 Tesaglitazar vs. Placebo
NCT00252837 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00252837 |
|---|---|
| Title | GALLANT 22 Tesaglitazar vs. Placebo |
| Official title | A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Behavioral, Drug |
| Interventions | Tesaglitazar, Dietary and Lifestyle counseling |
| Enrollment | 475 |
| Start date | Apr 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Nov 15, 2005 |
| Last update posted | Mar 17, 2008 |
| Countries | Australia, Czechia, Estonia, France, Greece, Hungary, Latvia, Lithuania, Norway, Philippines, Poland, Serbia and Montenegro and 2 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: